Their systemic anti-inflammatory effects, metabolic regulation, and influence on satiety and insulin sensitivity suggest they could help prevent the onset of multiple chronic conditions especially in high-risk populations
instead, they enhance the natural pathways already in place, giving patients a more sustainable way to reach metabolic balance
Nguyen DX, Bos PD, Massague J
Two things to look out for in the results While Eli Lilly is developing an oral GLP-1 agonist, Foundayo (orforglipron), it's a separate molecule from its leading subcutaneous Dual GLP-1/GIP agonist, Zepbound (tirzepatide)
Medications like Wegovy are known as GLP-1 agonists, and many of these drugs were initially prescribed to manage Type 2 diabetes but have since gained popularity for helping patients manage weight
Patients who start low and titrate gradually report better medication adherence, more sustainable appetite suppression, and fewer emergency medical visits for severe nausea or vomiting
